Literature DB >> 30073610

The role and strategy of ISoP in global pharmacovigilance.

Sten Olsson1, Mira Harrison-Woolrych2.   

Abstract

Applying the WHO definition of pharmacovigilance, the International Society of Pharmacovigilance, (ISoP) is concerned with all aspects of medicine safety. The safety of patients exposed to medicines depends on a wide variety of factors, where the understanding of each factor is associated with its own professional competence and skillset. For pharmacovigilance systems to work efficiently, a broad understanding of the necessary contribution of each of the different scientific competence areas and professional skills is required. ISoP is an independent, not-for-profit international professional organization, concerned with the best interest of patients exposed to pharmaceutical interventions in all healthcare systems in the world. ISoP offers an open platform for professionals from around the world with different expertise and skillsets, to network and exchange information and knowledge in a friendly environment. The society wishes to become a stronger global voice, speaking up in favour of patient safety and to be at the frontline of the global patient safety movement.

Entities:  

Keywords:  Drug safety; International association; Non-profit; Patient safety; Pharmacovigilance

Mesh:

Year:  2018        PMID: 30073610     DOI: 10.1007/s11096-018-0708-7

Source DB:  PubMed          Journal:  Int J Clin Pharm


  5 in total

1.  The ISoP CommSIG for Improving Medicinal Product Risk Communication: A New Special Interest Group of the International Society of Pharmacovigilance.

Authors:  Priya Bahri; Alexander N Dodoo; Brian D Edwards; I Ralph Edwards; Irene Fermont; Ulrich Hagemann; Kenneth Hartigan-Go; Bruce Hugman; Peter G Mol
Journal:  Drug Saf       Date:  2015-07       Impact factor: 5.606

2.  The New Phase of ISoP.

Authors:  Sten Olsson; Ian C K Wong; Jean-Christophe Delumeau; Mira Harrison-Woolrych
Journal:  Drug Saf       Date:  2017-10       Impact factor: 5.606

3.  Teaching pharmacovigilance: the WHO-ISoP core elements of a comprehensive modular curriculum.

Authors:  Jürgen Beckmann; Ulrich Hagemann; Priya Bahri; Andrew Bate; Ian W Boyd; Gerald J Dal Pan; Brian D Edwards; I Ralph Edwards; Kenneth Hartigan-Go; Marie Lindquist; John McEwen; Yola Moride; Sten Olsson; Shanthi N Pal; Rachida Soulaymani-Bencheikh; Marco Tuccori; Claudia P Vaca; Ian C K Wong
Journal:  Drug Saf       Date:  2014-10       Impact factor: 5.606

4.  Adverse drug reaction monitoring: doing it the French way.

Authors:  N Moore; M Biour; G Paux; E Loupi; B Begaud; F Boismare; R J Royer
Journal:  Lancet       Date:  1985-11-09       Impact factor: 79.321

5.  An Update on ISoP Special Interest Groups (SIGs).

Authors:  Deirdre McCarthy; Priya Bahri; Joanne Barnes; Jean-Christophe Delumeau; Brian Edwards; Mira Harrison-Woolrych
Journal:  Drug Saf       Date:  2018-01       Impact factor: 5.606

  5 in total
  1 in total

1.  Overview of this issue: pharmacovigilance, what is new?

Authors:  Linda Gore Martin; Yolande Hanssens; Vibhu Paudyal
Journal:  Int J Clin Pharm       Date:  2018-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.